Seasonal influenza causes significant morbidity and mortality in allogeneic stem cell transplant (SCT) recipients. In this population, influenza virus can replicate for prolonged periods, despite neuraminidase inhibitor treatment, leading to resistance and treatment failure. Baloxavir targets the influenza polymerase and may be an effective treatment option in these patients.

中文翻译：

---

Baloxavir用于治疗以前用奥司他韦治疗的异基因造血干细胞移植受体的流感。

季节性流感在同种异体干细胞移植（SCT）接受者中引起明显的发病率和死亡率。在该人群中，尽管使用神经氨酸酶抑制剂治疗，流感病毒仍可长时间复制，从而导致耐药性和治疗失败。Baloxavir靶向流感聚合酶，可能是这些患者的有效治疗选择。